Qiagen NV  

(Public, NASDAQ:QGEN)   Watch this stock  
Find more results for pcr
20.96
-0.01 (-0.05%)
After Hours: 20.95 -0.01 (-0.05%)
Apr 23, 5:16PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 20.86 - 21.26
52 week 18.30 - 24.82
Open 21.23
Vol / Avg. 0.00/1.28M
Mkt cap 4.90B
P/E 75.30
Div/yield     -
EPS 0.28
Shares 233.89M
Beta 0.85
Inst. own     -

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 16.61% 5.31%
Operating margin 9.42% 4.86%
EBITD margin - 9.11%
Return on average assets 5.91% 1.69%
Return on average equity 8.97% 2.54%
Employees 4,015 -
CDP Score - -

Address

Spoorstraat 50
VENLO, 5911 KJ
Netherlands
+31-77-3208400 (Phone)
+31-77-3208409 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

QIAGEN N.V., (QIAGEN) is a holding company, which provides sample and assay technologies. The consumable products such as sample and assay kits and automated instrumentation systems provides customers to transform raw biological samples into valuable molecular information.The Company serves four customer classes: Molecular Diagnostics laboratories; Applied Testing customers in fields such as forensics, veterinary diagnostics and food safety; Pharmaceutical research and development groups, and Academic researchers. The Company market its products in more than 100 countries. The Company offers more than 500 core consumable products as well as a number of instrument solutions to automate the processing of almost all QIAGEN products used for sample preparation and subsequent analysis. On May 3, 2012, the Company acquired AmniSure International LLC.

Officers and directors

Detlev H. Riesner Ph.D. Independent Chairman of the Supervisory Board
Bio & Compensation  - Reuters
Peer M. Schatz Chief Executive Officer, Managing Director
Bio & Compensation  - Reuters
Erik Hornnaess Independent Deputy Chairman of the Supervisory Board
Age: 75
Bio & Compensation  - Reuters
Roland Sackers Chief Financial Officer, Managing Director
Age: 44
Bio & Compensation  - Reuters
Thomas Schweins Senior Vice President - Human Resources, Strategy & Marketing Services
Bio & Compensation  - Reuters
Dietrich Hauffe Senior Vice President - Life Sciences Business Area
Age: 52
Bio & Compensation  - Reuters
Helge Lubenow Senior Vice President - Molecular Diagnostics Business Area
Bio & Compensation  - Reuters
Benedikt von Braunmuehl Senior Vice President - Global Commercial Operations
Bio & Compensation  - Reuters
Douglas Liu Vice President - Global Operations
Bio & Compensation  - Reuters
Ulrich Schriek Vice President - Corporate Business Development
Bio & Compensation  - Reuters